What is the clinical evidence from this study?

Study design: Review. Population: Patients treated with anthracycline-based chemotherapy including various cancers (breast, lymphoma, hematological malignancies), some with previous anthracycline exposure. Primary outcome: Prevention or reduction of anthracycline-induced cardiotoxicity measured by left ventricular ejection fraction (LVEF) decline, heart failure incidence, arrhythmia, cardiovascular mortality, or cardiac biomarkers.

What does this research mean for the field?

Pharmacologic interventions, including dexrazoxane, statins, beta-blockers, ACE inhibitors, and empagliflozin, significantly reduce the risk of anthracycline-induced cardiotoxicity and preserve cardiac function in cancer patients. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Open Access

Anthracyclines and the heart: A double-edged sword with therapeutic hopes

Key Result

Dexrazoxane reduced clinical heart failure risk by 68% (RR 0.32; 95% CI 0.20-0.50) and statins reduced LVEF decline and cardiotoxicity rates (OR 0.41; 95% CI 0.27-0.63) in patients receiving anthracyclines; β-blockers reduced symptomatic heart failure risk (RR 0.29; 95% CI 0.10-0.85) and preserved LVEF with a mean difference of 3.44%; enalapril and ramipril had modest LVEF preservation effects; empagliflozin reduced cardiac dysfunction risk by 82% (RR 0.18; p=0.01) in high-risk breast cancer patients

Key Points

Targeted strategies aim to mitigate anthracycline-induced cardiotoxicity and improve cardiac function.
Risk-based approaches using biomarkers and imaging have shown potential in offering protective benefits.
Further large-scale randomized studies are essential to identify the best combinations for cardioprotection.
The findings indicate a crucial need for more extensive research to confirm long-term benefits of these therapies.

Structured PICO

Do pharmacologic cardioprotective therapies limit anthracycline-induced cardiotoxicity and preserve cardiac function?

Population

Patients receiving anthracycline treatment

Intervention

Pharmacologic cardioprotective therapies

Outcome

Limiting anthracycline-induced cardiotoxicity and preserving cardiac function

Tailored, risk-based cardioprotective strategies guided by biomarkers and imaging show promise in limiting anthracycline-induced cardiotoxicity.

Limitations

Most randomized trials were small and had heterogeneous populations
Short follow-up durations limited assessment of long-term outcomes like heart failure hospitalization and cardiovascular mortality
Variable definitions of cardiac dysfunction and biomarker thresholds limited comparability
Few trials directly compared different pharmacologic agents or combinations
Majority of data came from early-stage breast cancer or hematologic malignancies limiting generalizability to other cancers
Unclear generalizability to patients with significant preexisting cardiac comorbidities
Narrative review methodology may introduce publication bias or selective reporting

Abstract

Several pharmacologic strategies offer potential benefit in limiting anthracycline-induced cardiotoxicity and preserving cardiac function. Tailored, risk-based approaches that incorporate cardioprotective therapies early in anthracycline treatment-guided by biomarkers and imaging-are most promising. Further large-scale randomised studies are required to establish optimal combinations and confirm long-term benefit.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Alotaibi et al. (Thu,) conducted a review in Patients treated with anthracycline-based chemotherapy including various cancers (breast, lymphoma, hematological malignancies), some with previous anthracycline exposure. Dexrazoxane reduced clinical heart failure risk by 68% (RR 0.32; 95% CI 0.20-0.50) and statins reduced LVEF decline and cardiotoxicity rates (OR 0.41; 95% CI 0.27-0.63) in patients receiving anthracyclines; β-blockers reduced symptomatic heart failure risk (RR 0.29; 95% CI 0.10-0.85) and preserved LVEF with a mean difference of 3.44%; enalapril and ramipril had modest LVEF preservation effects; empagliflozin reduced cardiac dysfunction risk by 82% (RR 0.18; p=0.01) in high-risk breast cancer patients.

synapsesocial.com/papers/69a7612fc6e9836116a2ee04 https://doi.org/https://doi.org/10.37616/2212-5043.1475

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: